RT Journal Article SR Electronic T1 Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.09.29.21264325 DO 10.1101/2021.09.29.21264325 A1 Andrew Levin A1 Nana Owusu-Boaitey A1 Sierra Pugh A1 Bailey K. Fosdick A1 Anthony B. Zwi A1 Anup Malani A1 Satej Soman A1 Lonni Besançon A1 Ilya Kashnitsky A1 Sachin Ganesh A1 Aloysius McLaughlin A1 Gayeong Song A1 Rine Uhm A1 Gideon Meyerowitz-Katz YR 2021 UL http://medrxiv.org/content/early/2021/10/01/2021.09.29.21264325.abstract AB Introduction The infection-fatality rate (IFR) of COVID-19 has been carefully measured and analyzed in high-income countries, whereas there has been no systematic analysis of age-specific seroprevalence or IFR for developing countries. Indeed, it has been suggested that the death rate in developing countries may be far lower than in high-income countries—an outcome that would be starkly different from the typical pattern for many other infectious diseases.Methods We systematically reviewed the literature to identify all serology studies in developing countries that were conducted using representative samples of specimens collected by early 2021. For each of the antibody assays used in these serology studies, we identified data on assay characteristics, including the extent of seroreversion over time. We analyzed the serology data using a Bayesian model that incorporates conventional sampling uncertainty as well as uncertainties about assay sensitivity and specificity. We then calculated IFRs using individual case reports or aggregated public health updates, including age-specific estimates whenever feasible.Results Seroprevalence in many developing country locations was markedly higher than in high-income countries but still far short of herd immunity. In most locations, seroprevalence among older adults was similar to that of younger age-groups. Age-specific IFRs were 1.3-2.5x higher than in high-income countries. The median value of population IFR was 0.5% among developing countries with satisfactory death reporting as of 2016, compared to a median of 0.05% for other developing countries.Conclusion The burden of COVID-19 is far higher in developing countries than in high-income countries, reflecting a combination of elevated transmission to middle-aged and older adults as well as limited access to adequate healthcare. These results underscore the critical need to accelerate the provision of vaccine doses to vulnerable populations in developing countries.Key Points‐ Age-specific prevalence and infection fatality rate (IFR) of COVID-19 for developing countries has not been well assessed.‐ Seroprevalence in developing countries (as measured by antibodies against SARS-CoV-2) is markedly higher than in high-income countries but still far short of herd immunity.‐ Seroprevalence among older adults is broadly similar to that of younger age-groups.‐ Age-specific IFRs in developing countries are roughly twice those of high-income countries.‐ Population IFR in developing countries with satisfactory death reporting (based on UN/WHO data as of 2016) is ten times higher than in other developing countries.‐ These results underscore the urgency of disseminating vaccines to vulnerable people in developing countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was not fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research required no ethical approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code will be available online shortly